Eris Lifesciences, one of the prominent players in the Indian pharmaceutical sector, recently witnessed a significant movement in its stock, touching a fresh all-time high of Rs 1,252.40 on the National Stock Exchange (NSE). This surge in share price comes on the back of a substantial block deal that saw 7.27% of the company’s equity change hands. Let’s delve deeper into the details of this deal and what it signifies for Eris Lifesciences and its stakeholders.
On Thursday, August 22, a massive block deal took place during the early trading hours. About 98.9 lakh shares, equivalent to 7.27% of Eris Lifesciences’ equity, were traded at Rs 1,201 per share, amounting to a total transaction value of Rs 1,187 crore. This pre-market block deal is noteworthy as it represents a significant portion of the company’s outstanding equity.
Interestingly, the identities of the buyer and seller involved in this substantial transaction have not yet been disclosed. The market is eagerly waiting to see who the major players behind this deal are, as it could potentially signal strategic moves within the company’s shareholder base.
Following the block deal, Eris Lifesciences’ stock continued its upward trajectory, trading at Rs 1,247.45 per share on the NSE, marking a nearly 3% increase. This marks the third consecutive day of gains for the stock, which has appreciated by 3.75% over this period. The stock opened with a gain of 2.24% today and reached an intraday high of Rs 1,252.40.
This block deal follows Franklin Templeton’s decision in July to raise its stake in Eris Lifesciences. The global investment firm acquired an additional 0.8% equity in the company, valued at Rs 109 crore, bringing its total stake to 2.26%. This increase from the previous 1.46% stake indicates Franklin Templeton’s growing confidence in Eris Lifesciences’ long-term potential.
Established in 2007, Eris Lifesciences has carved a niche for itself as a 100% domestic formulation company. As of March 31, 2024, the company’s promoters held a significant 54.90% stake. The company focuses primarily on the branded generics business, with a strong presence in the chronic (87% of sales) and acute segments (13% of sales).
Eris Lifesciences offers a wide range of products across various therapeutic areas, including anti-diabetes, cardiovascular, dermatology, gastroenterology, gynaecology, anti-infectives, vitamins, and other specialties. The company operates two manufacturing facilities, one in Guwahati, Assam, and the other in Ahmedabad, Gujarat, supported by a robust field force of 3,443 medical representatives and 1,415 field managers.
Eris Lifesciences continues to strengthen its position in the market with an impressive pipeline of products and a solid order book. In the first quarter of FY25, the company filed 185 new dossiers across 42 countries and introduced 11 new products in segments like ophthalmology, CNS, and antibiotics. With a research and development pipeline boasting over 90 products, Eris Lifesciences is well-positioned for future growth. Additionally, the company has a confirmed order book of approximately Rs 130 crore for delivery in FY25, highlighting its strong market demand.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
